Biotech Cat (@BiotechCat) header
Biotech Cat (@BiotechCat) profile picture

Biotech And More | Not Investment Advice | Will Make Mistakes, Always Learning | DMs Open

Joined April 2022
Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)
Biotech Cat retweeted
Sometimes when an analyst or investor sees the COO of a public biotech company spending a couple of weeks hiking to Everest basecamp while its stock is $0.30, they think that maybe they should be working harder to fix the situation the company is in.
16
8
10
141
86,661
TRAITS OF A GOOD ANALYST (1/2) Over the past several years I’ve had 6 analysts who at some point reported me, and have interacted with countless more.  These are the traits I’ve found to be most correlated with long term success. They probably aren’t what you think. A 🧵 What I don’t care about: Where you went to school, what banking program you did (or didn’t do), your test scores, your stock picking ability (initially). These are markers traditionally associated with success that IMO have little bearing on being a good analyst. What I do care about: An analyst’s job is to do excellent research in an intellectually honest, time efficient manner, and to communicate their findings clearly, succinctly, and accurately. Ideally they do this with as little oversight and friction as possible, allowing the fund to make more and better investments than they could without them. 1. Passion Some people love investing and researching companies - they just find it fun. If you find something fun, you tend to work harder at it and be better at it. Passion is also easy to screen for in a resume / interview. As a PM, it’s also energizing to work with passionate people who love the work. 2. Curiosity A lot of investing is asking the right questions. Curious people ask more and better questions. They go the extra distance vs. checking a box.  It’s often very small or incremental insights that make an idea or research better than another. 3. Humility / Open-mindedness - arrogance is a killer in this business.  On balance, smart people with “good” resumes tend to be more arrogant. Confirmation bias sinks analysts and sinks funds. Any hint of arrogance / confirmation bias is an automatic pass for us. 4. Attention to detail - careless mistakes in modeling erode trust and offset a lot of good and thoughtful work. They also require much more managerial oversight. It’s hard to be a good analyst if you frequently make mistakes or miss things. 5.  Trust / honesty  - PMs hire analysts to get leverage on their time - if your PM can’t trust you or your work, there is nowhere to go.  Admit your mistakes and make sure what you show the PM is accurate, even if it takes longer. Once trust is eroded it’s hard to get it back.
17
63
6
633
103,760
Who doesn't have a partnership with Merck these days?
4
6
110
9,210
Biotech Cat retweeted
CNBC is running a $NVDA earnings countdown like it’s New Year’s Eve. It was a good run everybody, it’s so over.
199
550
218
7,275
1,137,730
Biotech Cat retweeted
It’s 2024, are you even a real smid cap biotech if you don’t dilute shareholders with a pre-catalyst PIPE led by some combination of RA, TCGx, Frazier, or Venrock?
2
5
3
57
33,673
Biotech Cat retweeted
Funds don’t care either they will use the model as a template for their own assumptions. What’s more funny is when analyst assumptions don’t make logical sense- e.g., buy the stock on a binary catalyst of which I assign 20% probability of success to!
1
3
621
$IMGN Acquisitions are hard to predict, and shouldn’t form the bedrock of one’s investment thesis. That said, hard to think of a potential acquisition hiding in plain sight more clearly than $IMGN: - large candle block buys, in-session, in after hours, all forming the backbone of general recent trading volume that speaks of “informed/speculative” accumulation. - call option activity that is decidedly one-sided (in other words, not hedging/spread activity, but rather pure alpha play). - and the Goldman Sachs initiation of coverage, out of nowhere, at a neutral rating — no reason for this coverage other than to play some reindeer games. With the fundamentals of $IMGN evincing good reason for an acquisition — ELAHERE with strong initial demand/sales, and $IMGN team showing that they can put up those numbers unassisted. And with PICCOLO data seeming to corroborate ELAHERE potential in the more general OC population — platinum sensitive. And all in the hot sector of ADCs. Think that there is a bidding war ongoing — nothing Big Pharma wants more than little pharma that doesn’t need BP to launch a product because the product is just that good…
$IMGN $XBI Friday’s $XBI trade was punctuated by volume generally, but perhaps some particularly interesting candles in M&A-speculated $IMGN. Several green candles during market hours, the largest of which was for around $6mm block purchase. And then an after hours “candle” of roughly $14.5mm — representing the consolidated trading activity at close and in the after hours. Some notably large tranches purchased. Do we see a PR on Sunday evening/Monday morning?
4
5
2
43
25,049
Replying to @DrPaulyDeSantis
Why would anyone possibly want a better trastuzumab?
4
2
18
2,193
Maybe just the target was bad, and not the idea 🫠
1
14
3,470
Pitch consensus name is not make money. How to making money in biotech: 1. Go longed low volume smol cap name (e.g. $OCUL, $CMRX, $LRMR) 2. Formulate thesis on "stud" CEO and DCF with perpetual FCF 3. Tweet thesis to retail following 4. Watch stock upping
This quoted post is unavailable.
1
1
10
4,899
Name a more iconic duo than the D'Amelio twins I'll wait..
5
28
616
74,859
Biotech Cat retweeted
Where does $IMGN go if MIRASOL fails? Implied vol suggests ~ -20% but failure pretty much kills the ovarian cancer pipeline which leaves them with a CD123 asset in BPDCN (?) and a massive financial overhang. Cash is at ~$0.8
14%-20% sounds about right
2%-20-30%
22%-30-40%
62%-50% and lower
96 votes • Final results
5
1
4
3,192
Replying to @Gabby_Brauner27
What's wrong with Seattle? Go to monorail espresso and get a cappuccino and a chubby.
1
1
898
We must invest in this 4th gen TRK inhibitor bc Lilly bought Loxo for 8 billion
3
2
39
10,013
✳️Colorectal cancer is now the leading cause of cancer related death among males aged 20-39 and 40-49 ‼️It was third among 20-39 age group last year. ✳️ Concerning trend is also seen in young women; CRC related death and will likely surpass breast cancer in near future @OncoAlert
35
346
46
701
306,603
Biotech Cat retweeted
Replying to @PersimmonTI
What is a C-level position at $XBI companies like $AUPH $SGMO $CLVS?
1
5
Biotech Cat retweeted
Replying to @NimbusTx
@NimbusTx Ph2B allosteric TYK2 structure & property disclosure today @AmerChemSociety annual meeting nimbustx.com/2022/08/24/nimb…
1
5
22
Biotech Cat retweeted
No accelerated approval submission for FSGS for $TVTX. NDA submission 2H23 for full approval
2
2
1
11
Biotech Cat retweeted
Sums up $XBI
1
21
4
119